AVM Biotechnology Overview
- Year Founded
-
2008
- Status
-
Private
- Employees
-
10
- Latest Deal Type
-
Accelerator/Inc
- Latest Deal Amount
-
$25K
- Investors
-
6
AVM Biotechnology General Information
Description
Developer of a biotechnology platform designed to fight cancer, infectious diseases, and autoimmune disorders. The company's platform develops proprietary dexamethasone that mobilizes very active natural killer T-cells and is programmed to eliminate abnormal cells, whether cancer virus-infected, or autoreactive cells, enabling clinicians to provide immediate therapy for various diseases.
Contact Information
Website
www.avmbiotech.comCorporate Office
- 1700 7th Avenue
- Suite 2100
- Seattle, WA 98109
- United States
Corporate Office
- 1700 7th Avenue
- Suite 2100
- Seattle, WA 98109
- United States
AVM Biotechnology Timeline
AVM Biotechnology Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 15. Accelerator/Incubator | 09-Oct-2023 | $25K | Completed | Clinical Trials - Phase 2 | ||
| 14. Merger/Acquisition | 05-Dec-2022 | Cancelled | Clinical Trials - Phase 2 | |||
| 13. Grant | 14-Jun-2022 | Completed | Clinical Trials - Phase 2 | |||
| 12. Grant | 10-Jun-2022 | Completed | Clinical Trials - Phase 2 | |||
| 11. Grant | 05-Apr-2022 | Completed | Clinical Trials - Phase 2 | |||
| 10. Later Stage VC | 03-May-2021 | Completed | Clinical Trials - Phase 2 | |||
| 9. Grant | 31-Aug-2020 | Completed | Clinical Trials - Phase 2 | |||
| 8. Grant | 20-Sep-2019 | Completed | Clinical Trials - Phase 2 | |||
| 7. Later Stage VC | 07-May-2019 | $1.4M | $11.6M | Completed | Clinical Trials - Phase 2 | |
| 6. Later Stage VC (Series C) | 11-Dec-2017 | $5.51M | $10.2M | Completed | Clinical Trials - Phase 2 |
VC Exit Predictor
See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.
Opportunity Score
Calculated using Exit Type probabilities, the company’s stage, and PitchBook’s historical returns data.
Exit Type
Evaluates the likelihood of a successful exit for investors, and the most likely exit type.
AVM Biotechnology Comparisons
Industry
Financing
Details
AVM Biotechnology Competitors (40)
One of AVM Biotechnology’s 40 competitors is Brainstorm Cell Therapeutics, a Corporation company based in New York, NY.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Brainstorm Cell Therapeutics | Corporation | New York, NY | ||||
| Sernova | Corporation | London, Canada | ||||
| Qu Biologics | Venture Capital-Backed | Burnaby, Canada | ||||
| NexImmune | Formerly VC-backed | Gaithersburg, MD | ||||
| NeuroNascent | Venture Capital-Backed | Clarksville, MD |
AVM Biotechnology Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
AVM Biotechnology Patents
AVM Biotechnology Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| EP-4395784-A1 | Lymphocyte population and methods for producing same | Pending | 01-Sep-2021 | ||
| CA-3229529-A1 | Lymphocyte population and methods for producing same | Pending | 01-Sep-2021 | ||
| US-20240358829-A1 | Lymphocyte population and methods for producing same | Pending | 01-Sep-2021 | ||
| AU-2020451285-A1 | Methods of treatment using icam-modulating agents | Inactive | 01-Jun-2020 | ||
| CA-3180424-A1 | Methods of treatment using icam-modulating agents | Pending | 01-Jun-2020 | A61K31/573 |
AVM Biotechnology Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
AVM Biotechnology Investors (6)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| Life Science Washington Institute | Accelerator/Incubator | |||
| Small Business Innovation Research and Small Business Technology Transfer Programs | Government | |||
| National Cancer Institute | Government | |||
| National Institute of Diabetes and Digestive and Kidney Diseases | Government | |||
| National Institutes of Health | Government |
AVM Biotechnology FAQs
-
When was AVM Biotechnology founded?
AVM Biotechnology was founded in 2008.
-
Where is AVM Biotechnology headquartered?
AVM Biotechnology is headquartered in Seattle, WA.
-
What is the size of AVM Biotechnology?
AVM Biotechnology has 10 total employees.
-
What industry is AVM Biotechnology in?
AVM Biotechnology’s primary industry is Drug Discovery.
-
Is AVM Biotechnology a private or public company?
AVM Biotechnology is a Private company.
-
What is AVM Biotechnology’s current revenue?
The current revenue for AVM Biotechnology is .
-
How much funding has AVM Biotechnology raised over time?
AVM Biotechnology has raised $16.1M.
-
Who are AVM Biotechnology’s investors?
Life Science Washington Institute, Small Business Innovation Research and Small Business Technology Transfer Programs, National Cancer Institute, National Institute of Diabetes and Digestive and Kidney Diseases, and National Institutes of Health are 5 of 6 investors who have invested in AVM Biotechnology.
-
Who are AVM Biotechnology’s competitors?
Brainstorm Cell Therapeutics, Sernova, Qu Biologics, NexImmune, and NeuroNascent are some of the 40 competitors of AVM Biotechnology.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read blog » -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process »
